Thus, despite the increased levels of CCN2 observed in experimental and human cardiovascular diseases, including heart failure, pulmonary hypertension, restenosis, atherosclerosis or aortic aneurysms [9], the preclinical attempts to regulate CCN2 levels have led into mixed results. This evidence concerns the gene CCN2 and aortic aneurysm.